Xenetic reports Q2 2026 results, highlights DNase collaboration progress

Xenetic Biosciences reported financial results for the quarter ended June 30, 2026 in a release dated August 7, 2026, alongside an update on its DNase platform development work carried out through research collaborations rather than company-sponsored trials.

The company said positive preclinical and translational data presented at the 2026 American Society of Clinical Oncology Annual Meeting showed DNase I enhanced CAR T-cell expansion, persistence, tumor control and survival in preclinical models of blood cancers¹. Separately, Xenetic said its collaboration partner, PeriNess Ltd., obtained clearance from Israel's Ministry of Health and an Institutional Review Board to run an investigator-led exploratory study testing systemic recombinant human DNase I alongside anti-CD19 CAR T-cell therapy in large B-cell lymphoma patients at Tel Aviv Sourasky Medical Center¹.

On funding, the company said it collected roughly $1.5 million in royalty revenue over the first half of 2026¹. For the quarter itself, royalty revenue rose about 12% to roughly $0.7 million from about $0.6 million a year earlier, driven mainly by higher royalties under the sublicense deal with Takeda Pharmaceuticals Co. Ltd.¹ Research and development spending fell, while general and administrative costs climbed about 64% to roughly $1.1 million, largely reflecting legal costs tied to the company's ongoing strategic review¹.

Net loss for the quarter was about $0.9 million, versus about $0.7 million in the same period of 2025¹. Xenetic ended the quarter with approximately $6.5 million in cash and cash equivalents, down from about $7.9 million at the end of 2025¹. Interim CEO and CFO James Parslow said the company is directing capital toward work meant to inform future clinical development while continuing its strategic review process¹.